Summary
This European Heart Failure Association and EAPCI consensus statement synthesises clinical evidence on right-sided heart failure and tricuspid regurgitation, conditions that substantially impair quality of life and increase hospitalisation and mortality risk. The document elucidates aetiological and pathophysiological mechanisms to distinguish when tricuspid regurgitation is a secondary phenomenon versus a primary driver of heart failure progression. It provides practical guidance on early identification, diagnosis and current management options including medical therapy, surgery and emerging transcatheter interventions, though the statement acknowledges limited evidence on optimal patient selection and intervention timing.
UK applicability
As a European consensus statement issued by major cardiac societies, the clinical recommendations and diagnostic frameworks are directly applicable to UK heart failure services and cardiologists. The emphasis on early identification and multidisciplinary management aligns with NHS commissioning priorities for heart failure care.
Key measures
Clinical presentation, aetiology, pathophysiological mechanisms, quality of life impact, hospitalisation and mortality risk, diagnostic criteria, medical therapy efficacy, surgical and transcatheter intervention outcomes
Outcomes reported
The consensus statement synthesises current knowledge on epidemiology, pathophysiology, diagnosis and management of right-sided heart failure and tricuspid regurgitation, including medical and interventional treatment options. It provides practical recommendations for patient identification and management across European clinical practice.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.